- Report
- January 2022
- 40 Pages
France
From €1426EUR$1,500USD£1,198GBP
- Report
- January 2022
- 40 Pages
Germany
From €1426EUR$1,500USD£1,198GBP
- Report
- January 2022
- 40 Pages
Ireland
From €1426EUR$1,500USD£1,198GBP
- Report
- January 2022
- 40 Pages
Russia
From €1426EUR$1,500USD£1,198GBP
- Report
- January 2022
- 40 Pages
South Korea
From €1426EUR$1,500USD£1,198GBP
- Report
- January 2022
- 40 Pages
United States
From €1426EUR$1,500USD£1,198GBP
- Report
- January 2022
- 40 Pages
Vietnam
From €1426EUR$1,500USD£1,198GBP
The Non Hodgkin Lymphoma Drug market is a subset of the larger Lymphoma Drugs market. Non Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, and is the seventh most common cancer in the United States. Treatment for NHL typically involves chemotherapy, radiation, and targeted therapies. The Non Hodgkin Lymphoma Drug market is composed of a variety of drugs used to treat NHL, including monoclonal antibodies, small molecule drugs, and immunomodulators. These drugs are used to target specific proteins and pathways involved in the development and progression of NHL.
Some of the major companies in the Non Hodgkin Lymphoma Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Merck, Novartis, Pfizer, and Roche. Show Less Read more